Sign in
Taking peoplePhase 3

Efficacy and safety of adjunctive IgM-enriched immunoglobulin therapy with a personalized dose based on serum IgM-titers vs. standard dose in patients with septic shock. A multicenter, interventional, randomized, single-blinded, two arms, adaptive study design.

Key facts

Who runs it
Azienda Ospedaliero Universitaria Di Modena
Where
Italy9 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
356 people, planned
Started
11 Nov 2024
Planned end
19 Feb 2025
Type of study
Interventional
Record updated
4 April 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Age > 18 years; 2. Septic shock occurrence < 24 hours; septic shock is identified according to Sepsis-3 definition by a vasopressor requirement to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia in patients with sepsis2. Sepsis is defined as a life threatening organ dysfunction identified as an acute change in total SOFA score ≥2 points consequent to the infection; 3. IgM-titers< 60mg/dl (or < 20% of the lower threshold value of local laboratory) within 24 hours from shock occurrence

Who cannot take part

  • Shock of uncertain diagnosis; 2. Hypersensitivity to IgM Preparation in use or its excipients; 3. Patients receiving intravenous immunoglobulins (e.g. IgG or IgM enriched preparations) for > 6 hours before enrolment; 4. Selective absolute IgA deficiency with antibodies to IgA; 5. Pregnancy or breastfeeding or positive pregnancy test. In childbearing age women, before inclusion, a pregnancy test will be performed if not available; 6. Clinical decision to withhold life-sustaining treatment or “too sick to benefit”; 7. Neutrophil count <1.000/mm3; 8. Presence of other severe diseases impairing life expectancy (e.g. patients are not expected to survive 28 days given their pre-existing medical condition); 9. Patients with a known, chronic kidney dysfunction needing dialysis (creatinine ≥ 3.4 mg/dl or creatinine clearance ≤ 30 ml/min/1.73m2); 10. Body Mass Index (BMI) >40; 11. Participation in other clinical trials on adjunctive therapies for sepsis (during past 3 months); 12. Lack or withdrawal of informed consent

This trial is currently available in Italy.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective is to verify the hypothesis that an adjunctive therapy with IgM-enriched immunoglobulin with a personalized dose based on serum IgM-titers is more effective in reducing any-cause mortality in patients with septic shock compared to a flat dose therapy. Mortality will be measured at 28 days.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
4 April 2025